1. Home
  2. HUM vs ONC Comparison

HUM vs ONC Comparison

Compare HUM & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Humana Inc.

HUM

Humana Inc.

SELL

Current Price

$404.01

Market Cap

44.0B

Sector

Health Care

ML Signal

SELL

Logo BeiGene Ltd. American Depositary Shares

ONC

BeiGene Ltd. American Depositary Shares

N/A

Current Price

$361.83

Market Cap

40.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HUM
ONC
Founded
1961
2010
Country
United States
Switzerland
Employees
N/A
12000
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.0B
40.6B
IPO Year
2002
2015

Fundamental Metrics

Financial Performance
Metric
HUM
ONC
Price
$404.01
$361.83
Analyst Decision
Buy
Strong Buy
Analyst Count
26
28
Target Price
$423.74
★ $433.52
AVG Volume (30 Days)
★ 712.7K
350.9K
Earning Date
11-06-2026
11-10-2026
Dividend Yield
★ 0.88%
N/A
EPS Growth
N/A
★ 140.43
EPS
★ 9.83
0.31
Revenue
★ $129,664,000,000.00
$238,387,000.00
Revenue This Year
$25.51
$26.66
Revenue Next Year
$3.48
$14.52
P/E Ratio
★ $41.07
$1,167.29
Revenue Growth
10.11
★ 22179.16
52 Week Low
$163.11
$253.95
52 Week High
$428.88
$385.22

Technical Indicators

Market Signals
Indicator
HUM
ONC
Relative Strength Index (RSI) 59.67 53.82
Support Level $385.22 $327.01
Resistance Level $419.36 $370.11
Average True Range (ATR) 12.76 7.60
MACD 1.44 -0.23
Stochastic Oscillator 82.66 62.80

Price Performance

Historical Comparison
HUM
ONC

About HUM Humana Inc.

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

About ONC BeiGene Ltd. American Depositary Shares

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

Share on Social Networks: